Back to results
US 10,472,351 B2Granted
Small molecule agonists and antagonists of NR2F6 activity in animals
AssigneeZander Therapeutics, Inc.
InventorsHarry M. Lander, David R. Koos
Life of this patent
Estimating the term…
Abstract
The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein to animals.
Claims3
A compound having a structure of any of the following:
- wherein the compound is in solid form with a pharmaceutically acceptable carrier or excipient.
Dependencies are inferred from the claim text.